This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (7) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mohl, A. Articles by Medori, R. Search for Related Content PubMed PubMed Citation Articles by Mohl, A. Articles by Medori, R. Social Bookmarking                         What's this?

Long-acting risperidone in stable patients with schizoaffective disorder

Psychiatrische Dienste Aargau AG, EPD, Baden, Switzerland, andreas.mohl{at}pdag.ch

K. Westlye

Jæren DPS, Bryne, Norway

S. Opjordsmoen

Department of Psychiatry, Ulleval University Hospital, Oslo, Norway

A. Lex

Janssen-Cilag, Medical Affairs EMEA, Beerse, Belgium

A. Schreiner

Janssen-Cilag GmbH, Neuss, Germany

M. Benoit

CHU de Nice, Nice, France

P. Bräunig

Klinikum Chemnitz GmbH, Chemnitz, Germany

R. Medori

Janssen-Cilag, Medical Affairs EMEA, Beerse, Belgium

Oral and long-acting risperidone has been shown to be effective for acute and maintenance treatment of patients with schizoaffective disorders. The present analysis investigated the efficacy and tolerability of direct transition from other antipsychotics to risperidone long-acting injectable in patients with schizoaffective disorder.

Patients aged 18 years with schizoaffective disorder (DSM-IV), who required a change of medication, received risperidone long-acting injectable 25mg (increased to 37.5 or 50mg, if necessary) every 2 weeks for 6 months.

The analysis included 249 patients (47% male; mean age 43 years), of whom 74% completed the 6-month study. Mean scores for the total Positive and Negative Syndrome Scale (PANSS) and all three subscales were significantly reduced from baseline to week 4 (p < 0.001), with further improvements until treatment endpoint. Significant improvements from baseline to endpoint were seen in the mood symptom domains of anxiety/depression (10.4±4.1 vs 8.7±3.9) and uncontrolled hostility/excitement (7.6±3.6 vs 6.9±3.8). Mean Global Assessment of Function (GAF) score improved significantly from 59.4±15.6 at baseline to 66.4±17.7 (p < 0.001) at endpoint. Of 87 patients hospitalized at baseline, 67% were discharged at endpoint. Both quality of life (SF-36) and satisfaction with treatment were improved significantly at endpoint. Total ESRS scores fell progressively throughout the study, and the reduction was already statistically significant (p < 0.001) at 4 weeks. Small but statistically significant (p < 0.001) mean shifts of 1.8% were seen in body weight and Body Mass Index (BMI).

Patients with schizoaffective disorder derived several benefits from a change to risperidone long-acting injectable, including reductions in psychiatric symptoms (particularly the mood symptom domains) and a reduction in the severity of drug-induced neurological movement disorders.

Key Words: risperidone • schizoaffective • long-acting • antipsychotics for injection • efficacy • safety

Journal of Psychopharmacology, Vol. 19, No. 5 suppl, 22-31 (2005)
DOI: 10.1177/0269881105056515


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. Chue The relationship between patient satisfaction and treatment outcomes in schizophrenia J Psychopharmacol, November 1, 2006; 20(6_suppl): 38 - 56. [Abstract] [PDF]